MPG.eBooks - Description: CADTH Canadian Drug Expert Committee final recommendation: Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus

Cover Image

Read Now

CADTH Canadian Drug Expert Committee final recommendation: Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus

The CADTH Canadian Drug Expert Committee (CDEC) recommends that canagliflozin and metformin hydrochloride (canagliflozin/metformin) be reimbursed for patients with type 2 diabetes mellitus provided that criterion and condition are met

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, August 25, 2016
Series:	Common drug review
Subjects:	Insurance, Health, Reimbursement Metformin / Therapeutic Use Canada Canagliflozin / Therapeutic Use Diabetes Mellitus, Type 2 / Drug Therapy Drug Costs
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK540288
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that canagliflozin and metformin hydrochloride (canagliflozin/metformin) be reimbursed for patients with type 2 diabetes mellitus provided that criterion and condition are met
Physical Description:	1 PDF file (5 pages)